Onconetix, Inc. (NASDAQ:ONCO) Short Interest Up 365.3% in January

Onconetix, Inc. (NASDAQ:ONCO) was the target of a large increase in short interest in January. As of January 15th, there was short interest totalling 266,600 shares, an increase of 365.3% from the December 31st total of 57,300 shares. Based on an average daily volume of 5,240,000 shares, the days-to-cover ratio is presently 0.1 days. Approximately 7.6% of the shares of the stock are sold short.

Institutional Investors Weigh In On Onconetix

An institutional investor recently raised its position in Onconetix stock. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Onconetix, Inc. (NASDAQ:ONCO) by 83.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 562,691 shares of the company’s stock after acquiring an additional 256,612 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank owned 76.04% of Onconetix worth $2,926,000 at the end of the most recent quarter. 23.89% of the stock is owned by institutional investors.

Onconetix Stock Down 6.8 %

Shares of ONCO traded down $0.04 during midday trading on Tuesday, hitting $0.60. 3,222,243 shares of the company traded hands, compared to its average volume of 14,808,322. Onconetix has a 52 week low of $0.32 and a 52 week high of $21.40. The firm has a 50 day moving average of $0.59 and a 200-day moving average of $3.39.

Onconetix (NASDAQ:ONCO) last released its quarterly earnings results on Monday, December 9th. The company reported ($2.24) earnings per share for the quarter.

Onconetix Company Profile

Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer.